Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 clinical trial with the imaging agent for the detection of nodal metastases in HER2+ breast cancer patients

Next Previous
Trial Profile

A Phase 2 clinical trial with the imaging agent for the detection of nodal metastases in HER2+ breast cancer patients

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MSH 2IA (Primary)
  • Indications HER2 positive breast cancer
  • Focus Diagnostic use

Most Recent Events

  • 16 Feb 2026 New trial record
  • 03 Feb 2026 According to Imagion Biosystems media release, company has lodged an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its MagSense targeted imaging agent. The company anticipates enrollment for the Phase 2 trial could begin as early as Q1 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top